Interní Med. 2012; 14(10): 378-382

Fabry disease - lysosomal storage disease with multiorgan involvement

MUDr.Lubor Goláň
II. interní klinika VFN a 1. LF UK

Fabry disease is an inherited lysosomal storage disorder. The inheritance is gonosomal recessive but females can also be involved. A gene

mutation causes a shortage of the enzyme α-galactosidase A leading to storage of globotriaosylceramide in cells of various tissues

and their damage. It is a rare disease which manifests in childhood with symptoms secondary to peripheral nerve involvement (paresthesias,

pain of extremities, fevers). Hypertrophic cardiomyopathy and renal disease leading to failure of function are characteristic.

Involvement of central nervous system, gastrointestinal tract, ear and vestibular apparatus may also be present. Typical manifestations

are angiokerathomas of skin and corneal opacities called cornea verticillata. The treatment consists of enzyme substitution of missing

enzyme and control of symptoms. There are 3 case reports demonstrating the serious involvement in Fabry disease discussed in the paper.

Keywords: Fabry disease, hypertrophic cardiomyopathy, renal failure, lysosomal storage disease

Published: November 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Goláň L. Fabry disease - lysosomal storage disease with multiorgan involvement. Interní Med. 2012;14(10):378-382.
Download citation

References

  1. Desnick RJ, Brady R, Barranger J. Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy. Ann Intern Med. 2003; 138: 338-346. Go to original source... Go to PubMed...
  2. Dobrovolny R, Dvorakova L, Ledvinova J. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med. 2005 Aug; 83(8): 647-654. Epub 2005 Apr 2. Go to original source... Go to PubMed...
  3. Elleder M. Sequelae of storage in Fabry disease-pathology and comparison with other lysosomal storage diseases. Acta Paediatr Suppl. 2003 Dec; 92(443): 46-53. Go to original source... Go to PubMed...
  4. Baehner F, Kampmann C, Whybrae C. Enzyme replacement therapy in heterozygot females with Fabry disease: Results of a phase IIIB study. J Inherit Metab Dis 26; 2003; 26: 617-662. Go to original source... Go to PubMed...
  5. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9-16. Go to original source... Go to PubMed...
  6. Thurberg BL, Byers HR, Granter SR, et al. Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol 2004; 122: 900-908. Go to original source... Go to PubMed...
  7. Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007; 146: 77-86. Go to original source... Go to PubMed...
  8. Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008; 94: 153-158. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.